Saturday 17 October 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3% and free cash flow grew 7.91%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.
3.38
0.22
−6.11%
Follow ANTX
AN2 Therapeutics, Inc. (ANTX) P/E ratio
AN2 Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| ANTX AN2 Therapeutics, Inc. | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| CUE Cue Biopharma, Inc. compare | n/m |
| KRRO Korro Bio, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)